GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline ...

Comparatively, GSK underperformed the UK market's 3% decline and the UK Pharmaceuticals industry's 4.8% dip over the last year, highlighting industry-wide pressures.

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

GSK has underperformed the broader markets and most of its big pharma peers over the last 10 years. With a tighter focus on branded pharma products, GSK arguably deserves another look by investors ...

Reckitt agrees sale of Cillit Bang division 07:25 , Graeme Evans A portfolio of Reckitt Benckiser ...

For new and old investors, taking full advantage of the stock market and investing ... likelihood its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of ...